Loading...
•
Dec 31, 2020
Novavax Q4 2020 Earnings Report
Announced fourth quarter and full year 2020 financial results and operational highlights.
Key Takeaways
Novavax reported a net loss of $177.6 million, or $2.70 per share, for the fourth quarter of 2020. Novavax revenue in the fourth quarter of 2020 was $279.7 million.
Novavax continues to make significant strides towards bringing NVX-CoV2373, their COVID-19 vaccine candidate, to market.
NVX-CoV2373 offers a highly unique profile, including the ability to ship and store the vaccine at traditional refrigerated temperatures.
Novavax has secured agreements for the delivery of approximately 300 million doses of NVX-CoV2373.
Novavax is partnering with the Serum Institute of India to jointly supply 1.1 billion doses of NVX-CoV2373 to Gavi through the COVAX Facility.
Novavax
Novavax
Forward Guidance
Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements.